Clinical Trial: Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

Brief Summary: Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.

Detailed Summary:
Sponsor: Dr Ahmed Ali Elbaz

Current Primary Outcome: Organisms detected with their antibiotics sensitivity [ Time Frame: 8 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Nasser Institute For Research and Treatment

Dates:
Date Received: March 9, 2015
Date Started: March 2015
Date Completion:
Last Updated: June 3, 2015
Last Verified: June 2015